Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review reports that microneedle-mediated transdermal drug delivery systems show promise in enhancing alopecia treatments by improving the efficacy of various therapeutic agents, including drugs, biologics, and stem cells, but highlights a gap between basic research advancements and clinical trial focus.

Hidradenitis Suppurativa is a chronic skin condition best treated early with surgery for better outcomes and less recurrence.

This review explores how molecular profiling in atopic dermatitis has led to new therapeutic developments, detailing approved and potential treatments, and discusses similar advances in alopecia areata; it reports no new results.

This guideline outlines the management of systemic lupus erythematosus in adults but reports no new clinical findings.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.

This study reviewed evidence on biologic drugs targeting immune cells for alopecia areata, finding mixed results: some achieved case-level hair regrowth, but controlled trials often showed limited efficacy.

In this study, data from the FAERS database indicated varied associations between certain medications and obstructive sleep apnea, with some biologics associated with a decreased risk of developing the condition.

This review summarizes various drug treatments for hidradenitis suppurativa, noting their effectiveness, side effects, and high recurrence rates, but reports no new clinical findings.

This study explores the development of a liposomal gel containing andrographolide from the plant Andrographis paniculata to potentially improve psoriasis management by enhancing drug delivery and reducing side effects of conventional treatments.

In this retrospective study, researchers found a statistically significant increase in the risk of alopecia areata among atopic dermatitis patients using dupilumab compared to controls, suggesting the need for careful monitoring and further research on the drug's impact on alopecia areata.

This study discusses how emerging biologics and small molecule therapies could enhance disease management and pediatric health outcomes for chronic skin conditions, suggesting their potential inclusion in treatment guidelines pending ongoing clinical trial successes.

This review discusses possible medication-induced hair loss and the need to exclude other confounding factors like stress and illness; it reports no new clinical findings and emphasizes careful assessment before attributing hair loss to medications.

In this study, JAK inhibitors were reported as safe and effective treatments for moderate-to-severe chronic alopecia areata, although the appropriate duration of treatment remains uncertain, as stopping these medications often results in relapse.

This study analyzed adverse event reports from the FDA database and found that drugs such as immunomodulatory agents, monoclonal antibodies, minoxidil, contraceptives, and anti-TNF drugs are frequently associated with hair loss, suggesting guidance for dermatologists in identifying common medications linked to alopecia.

This CADTH recommendation advises that Olumiant should be publicly reimbursed for treating severe alopecia areata in adults, provided conditions such as a 50% scalp hair loss and specific prescribing criteria are met.

New acne treatments show promise as alternatives to traditional therapies.

In this report, a 35-year-old female with palmoplantar pustulosis undergoing secukinumab treatment developed alopecia areata, a rare side effect attributed to paradoxical reactions with IL-17 inhibitors; switching to tofacitinib improved both conditions.

This review explores the causes and mechanisms of alopecia areata and discusses current treatments, reporting no new clinical findings.

The EADV Task Force on Hair Diseases reviewed existing literature and clinical experience to propose diagnostic and therapeutic recommendations for managing folliculitis decalvans, highlighting oral antibiotics, glucocorticosteroids, isotretinoin, and various systemic and topical therapies as key options for managing inflammation and preventing further hair loss.

This study examined the market trends for biologics that have lost patent exclusivity and predicted that drugs like adalimumab, once facing competition, could see price reductions and decreased market share, although the impact on accessibility and total patient use remains unclear.

This review describes bioengineering strategies to mimic the natural cell microenvironment in vitro, emphasizing the novel approach of using cell-synthesized extracellular matrix as a scaffold for engineering functional 3D tissues, while highlighting the limitations of exogenous scaffolds in tissue engineering.

This article discusses the biologic and psychosocial significance of hair, the current limitations in hair growth drugs, and anticipates future therapies based on advancing hair follicle research.

This report reviews peer-reviewed case studies indicating potential efficacy of ustekinumab for treating challenging forms of psoriasis but notes the need for further research on cost-effectiveness and risk-benefit.

This study found that baricitinib improved symptoms of atopic dermatitis and alopecia areata in both adults and children in real-world settings, aligning with clinical trial results, while noting low discontinuation due to adverse events and no new safety concerns.

This review discusses the complexities of managing adolescent psoriasis amidst challenges like identity formation and parent-adolescent dynamics, and proposes updated management strategies for 21st-century adolescents, but reports no new clinical results.

This study observed that dermatologists predominantly prescribed topical treatments for skin disorders in pregnant women, with pruritus and urticaria being the most common conditions.

Understanding drug effects and careful monitoring are crucial for safe and effective dermatology treatments.

Organizations help patients access discounts for expensive dermatology medications.

The document summarizes important skin care topics for non-specialist doctors, including treatments for skin conditions and the management of skin diseases.

In this case report, the researchers observed that combining growth hormone therapy with the biologic drug dupilumab effectively improved growth and health outcomes in a patient with Netherton syndrome and comorbid hypopituitarism, suggesting a multidisciplinary approach may be beneficial for managing such cases.